Where this information comes from
Retatrutide has published phase 2 results. Adverse events were recorded systematically, against a placebo arm, by investigators following a protocol. That is the only source of comparative safety information that currently exists for this compound.
The reported profile was dominated by gastrointestinal effects: nausea, diarrhoea, vomiting and constipation, generally described as mild to moderate and more frequent at higher doses and during escalation. This is consistent with the incretin class as a whole and follows from slowed gastric emptying.
What a phase 2 trial cannot tell you is what happens rarely, or what happens over years. Several hundred participants under a year is enough to characterise common effects and not enough to characterise uncommon ones. That is what phase 3 is for, and it has not reported.
The primary record of retatrutide side effects is the trial registry and the papers, not any summary of them. The retatrutide entries on ClinicalTrials.gov list the phase 2 study and the phase 3 programme that has yet to report, with their designs, arms and status, and the published papers indexed on PubMed carry the adverse-event tables themselves. A table gives you the denominator, the comparison arm and the definition of each event, which are exactly the three things a secondhand account tends to drop.
Four things the data does not settle
Being specific about the limits is more useful than a list of symptoms.
Why anecdotal reports read differently
Self-reported experience has no placebo arm, no systematic collection and heavy selection: people with something notable to report are far more likely to post than people with nothing. Both dramatic and uneventful experiences are under-representative, in opposite directions.
That does not make anecdote worthless. It is often where a signal first appears, and dismissing it entirely is its own kind of error. It does mean it cannot be read as though it were trial data.
The useful habit is knowing which you are looking at. A trial tells you what happened in a defined group under defined conditions. A forum tells you what somebody chose to write down.
One further source needs separating out: reports that have nothing to do with the compound. Material bought without documentation may contain less than the label states, may have degraded, or may be a different substance altogether, and whatever follows from that is not an effect of retatrutide. The degradation page describes what a compromised vial looks like, and the guide to fake certificates is the check that removes the question before it arises.
- Percentages quoted without a denominatorA frequency means nothing without the number of participants and the comparison arm.
- Comparisons across different trialsDifferent populations, doses and durations. Side-effect rates are not portable between studies.
- Absence read as safetyNot reported in a small trial is not the same as does not occur.
- Forum consensus treated as evidenceAgreement among posters measures who posts, not what is true.
Read alongside
Three pages that give this one its context.
About the reported effects
The questions this page is usually reached by.